Daniel De La Nava-De La Mano

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Journal: Research square
Published: July 03, 2026

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Combinatorial Targeting of Avapritinib-Driven MAP Kinase Activation in High-Grade Glioma.

Journal: Research square
Published: July 03, 2026

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

Journal: Neuro-oncology
Published: March 30, 2024

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.

Journal: JCI insight
Published: August 29, 2023

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

Journal: Cancer cell
Published: February 07, 2023

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Journal: Cancer discovery
Published: January 29, 2023

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Journal: Molecular therapy oncolytics
Published: April 04, 2022

Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.

Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.

Journal: Frontiers in immunology
Published: January 31, 2022

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Journal: JCI insight
Published: September 14, 2021

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Journal: Molecular cancer therapeutics
Published: June 29, 2021

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

Journal: Journal for immunotherapy of cancer
Published: June 16, 2021

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma.

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma.

Journal: Frontiers in cell and developmental biology
Published: February 24, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026